Nab-placlitaxel

Phase 2Small molecule

Nab-placlitaxel is one of 10 small molecule programs targeting Locally Advanced Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Breast CancerActive, not recruiting

Locally Advanced Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Locally Advanced Breast Cancer

#DrugCompanyPhaseTrials

Herceptin

OOrganon and Co

Phase 3

1 2

Taxotere

AAvyxa

Phase 3

1 3

Taxol

Teva

Phase 2

1 4

Halaven

Eisai

Phase 2

1 5

Gemzar

Johnson & Johnson

Phase 2

1 6

Paraplatin

AAvyxa

Phase 2

1 7

BNT327 Optimized Dose

BioNTech

Phase 2

1 8

DL2

Sun Pharma Advanced Research Company Limited

Phase 2

1 9

BNT327

BioNTech

Preclinical

1 10

Nab-placlitaxel

BioNTech

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

Locally Advanced Breast Cancer

NCT06449222

Clinical

Trials by Indication[1]

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449222·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nab-placlitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nab-placlitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nab-placlitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BioNTech

Nab-placlitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News